BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33240237)

  • 1. A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy.
    Cong J; Zhang Y; Xue Y; Zhang C; Xu M; Liu D; Zhang R; Zhu H
    Front Microbiol; 2020; 11():583525. PubMed ID: 33240237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients.
    Zheng Q; Hong S; Huang Y; Zhao H; Yang Y; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Clin Transl Med; 2020 Feb; 9(1):17. PubMed ID: 32067121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine.
    Aarnoutse R; Ziemons J; de Vos-Geelen J; Valkenburg-van Iersel L; Wildeboer ACL; Vievermans A; Creemers GM; Baars A; Vestjens HJHMJ; Le GN; Barnett DJM; Rensen SS; Penders J; Smidt ML
    Clin Colorectal Cancer; 2022 Jun; 21(2):e87-e97. PubMed ID: 34801414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Study: Favorable Effects of
    Cong J; Zhang C; Zhou S; Zhu J; Liang C
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
    Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis.
    Zhao Z; Li L; Wang Z; Duan J; Bai H; Wang J
    J Cancer; 2020; 11(11):3106-3113. PubMed ID: 32231715
    [No Abstract]   [Full Text] [Related]  

  • 9. Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls.
    Aarnoutse R; Hillege LE; Ziemons J; De Vos-Geelen J; de Boer M; Aerts EMER; Vriens BEPJ; van Riet Y; Vincent J; van de Wouw AJ; Le GN; Venema K; Rensen SS; Penders J; Smidt ML
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intestinal colonization by Clostridium difficile and Staphylococcus aureus on microbiota diversity in healthy individuals in China.
    Dong D; Ni Q; Wang C; Zhang L; Li Z; Jiang C; EnqiangMao ; Peng Y
    BMC Infect Dis; 2018 May; 18(1):207. PubMed ID: 29724187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients.
    Zhang W; Luo J; Dong X; Zhao S; Hao Y; Peng C; Shi H; Zhou Y; Shan L; Sun Q; Li Y; Zhao X
    J Cancer; 2019; 10(7):1651-1662. PubMed ID: 31205521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.
    Santos ES; Kaplan B; Kirshner E; Croft EF; Sequist LV; Chau M; Munley J; Oxnard GR
    Oncol Ther; 2018 Jun; 6(1):45-58. PubMed ID: 32700141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
    Doval DC; Desai CJ; Sahoo TP
    Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
    Mintz M; Khair S; Grewal S; LaComb JF; Park J; Channer B; Rajapakse R; Bucobo JC; Buscaglia JM; Monzur F; Chawla A; Yang J; Robertson CE; Frank DN; Li E
    PLoS One; 2018; 13(1):e0190997. PubMed ID: 29385143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of
    Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
    Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
    [No Abstract]   [Full Text] [Related]  

  • 16. Fecal metabonomics combined with 16S rRNA gene sequencing to analyze the changes of gut microbiota in rats with kidney-yang deficiency syndrome and the intervention effect of You-gui pill.
    Chen R; Wang J; Zhan R; Zhang L; Wang X
    J Ethnopharmacol; 2019 Nov; 244():112139. PubMed ID: 31401318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy Alters the Phylogenetic Molecular Ecological Networks of Intestinal Microbial Communities.
    Cong J; Zhu J; Zhang C; Li T; Liu K; Liu D; Zhou N; Jiang M; Hou H; Zhang X
    Front Microbiol; 2019; 10():1008. PubMed ID: 31134034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of curative resection on fecal microbiota in patients with colorectal cancer: a prospective pilot study.
    Park SS; Kim B; Kim MJ; Roh SJ; Park SC; Kim BC; Han KS; Hong CW; Sohn DK; Oh JH
    Ann Surg Treat Res; 2020 Jul; 99(1):44-51. PubMed ID: 32676481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential flora in the microenvironment of lung tumor and paired adjacent normal tissues.
    Mao Q; Ma W; Wang Z; Liang Y; Zhang T; Yang Y; Xia W; Jiang F; Hu J; Xu L
    Carcinogenesis; 2020 Aug; 41(8):1094-1103. PubMed ID: 32658980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC.
    Sidaway P
    Nat Rev Clin Oncol; 2024 Jun; ():. PubMed ID: 38886612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.